Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 150,289	$ 136,604
Short-term investments	29,359	0
Accounts receivable	4,754	153
Prepaid expenses and other current assets	3,801	2,938
Total current assets	188,203	139,695
Investments at fair value	63,657	104,754
Investment - other	8,195	2,195
Patents, net	56,587	61,917
Other assets	1,193	207
Total assets	317,835	308,768
Current liabilities:
Accounts payable and accrued expenses	9,040	7,956
Royalties and contingent legal fees payable	39,937	1,601
Total current liabilities	48,977	9,557
Other liabilities	1,805	3,552
Total liabilities	50,782	13,109
Commitments and contingencies (Note 6)
Stockholders' equity:
Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; no shares issued or outstanding	0	0
Common stock, par value $0.001 per share; 100,000,000 shares authorized; 50,647,882 and 50,639,926 shares issued and outstanding as of March 31, 2018 and December 31, 2017, respectively	51	51
Treasury stock, at cost, 1,729,408 shares as of March 31, 2018 and December 31, 2017	(34,640)	(34,640)
Additional paid-in capital	649,724	648,996
Accumulated comprehensive loss	(125)	(88)
Accumulated deficit	(349,550)	(320,018)
Total Acacia Research Corporation stockholders' equity	265,460	294,301
Noncontrolling interests in operating subsidiaries	1,593	1,358
Total stockholders' equity	267,053	295,659
Total liabilities and stockholders' equity	$ 317,835	$ 308,768